Long‐term response to afatinib in an elderly patient with uncommon epidermal growth factor receptor mutation‐positive lung adenocarcinoma

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are the standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR mutations. Uncommon mutations, excluding exon 19 deletions and exon 21 L858R, comprise 7%–23% of EGFR mutation‐positive NSCLC. The treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Shijubou, Naoki, Sumi, Toshiyuki, Kamada, Koki, Sawai, Takeyuki, Yamada, Yuichi, Nakata, Hisashi, Mori, Yuji, Chiba, Hirofumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952783/
https://www.ncbi.nlm.nih.gov/pubmed/33533191
http://dx.doi.org/10.1111/1759-7714.13869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952783/
https://www.ncbi.nlm.nih.gov/pubmed/33533191
http://dx.doi.org/10.1111/1759-7714.13869

Ejemplares similares